U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form: 1449/PTO

Complete if Known	Application Number	10/521928	
INFORMATION DISCLOSURE	Filling Date	July 29, 2003	
STATEMENT BY APPLICANT	(Use as many sheets as necessary)	Art unit	1627
Sheet	1	of	2

						Examiner Name	Javanmard, Sahar	
Sheet		1	1 64 6		Attorney Docket Number		PAT032602-US-PCT	
				U.S.	PATENT DO	CUMENTS		
Examiner Indials*	Cite No.	Document Number  Number-Kind Code <sup>2 of source</sup>			Psublication Date MM-DD-YYYY	Name of Paterilise of Applicant of Cited Documer	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appelar	
		US-						
		US- US- US- US- US- US-						
								**********
								·
		US-						
		ÚŚ-	***************************************			· · · · · · · · · · · · · · · · · · ·		
		US	***************************************					**********
		US-	***************************************					•••••
	••••••	US-						
	······	US-	***************************************					
	<del></del>	US-						
		***************************************		FOREIG	N PATENT D	OCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-00-YYYY		Pages, Columns, Lines, where Relevant Passages, C Relevant Figures Appear		
HHOSES.	1962:	Country Code <sup>®</sup> Number <sup>®</sup> Kind Code <sup>® Shows</sup>					Whitesau or Custo pocoun	
		JP62212369 (A	bstract)	····	9/18/1987			1
			***********	····				7
	····			***************************************				[.
								1.
								[
								Į.
- xamin			••••••••••••		***************************************	Date	· · · · · · · · · · · · · · · · · · ·	*********

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFB 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFB 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1905, no persons are required to respond to a collection of information unless if contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/521928 INFORMATION DISCLOSURE Filing Date July 29, 2003 First Named Inventor Bhatnagar, Ajay S. et al. STATEMENT BY APPLICANT Art unit (Use as many sheets as necessary) **Examiner Name** Javanmard, Sahar Sheet of PAT032602-US-PCT Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	·····
Examine: Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	18
		Cohen, Martin H et al., "Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer", Clinical Cancer Research, Vol 8, pp. 65-669, 2002	
		Coleman R.E., "Metastatic bone disease: clinical features, pathophysiology and treatment strategies",Cancer Treatment Reviews, Vol. 27, pp. 165-178, 2001	
		Hillner, Bruce E. et al., "American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer", Journal of Clinical Oncology, Vol. 18, No 6, pp. 1378-1391, 2000	
		Chinese New Drugs Journal, Vol. 8, No. 6, pp 374-376, 1999 (Abstract)	
		Neville_Webbe, H. L. [Reprint Author): Lefley, D.; Coleman, R.E., Hoten, I., Bone (New York), Vol. 38, No. 3, Suppl. 1, pp. 958-959, Meeting Info.: 11* and Valedictory Workshop on Cell Biology of Bone and Cartilage in Health and Disease, Davos, Swifzerland, March 18-21, 2006, CODEN: BONEDL, ISSN: 8756-3282	
Examin		Date	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include conv. of this form with the next communication to applicant.

Considered

Signature

and not considered. Include copy of this form with the next communication to applicant.

Applicant's unique ditation designation number (optional). Applicant is to place a check mark here it English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.